WHAT IS CLAIMED IS:

1. A compound of the formula A:



A

wherein:

R^{1a} is independently selected from:

a) hydrogen,

b) aryl, heterocycle, C_3-C_{10} cycloalkyl, $R^{10}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NR^{10}$-, $(R^{10})_2N$-C(O)-, CN, NO_2, $(R^{10})_2N$-C(NR^{10})-, $R^{10}C(O)$-, $R^{10}OC(O)$-, -$N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$-,

c) unsubstituted or substituted C_1-C_6 alkyl, unsubstituted or substituted C_2-C_6 alkenyl or unsubstituted or substituted C_2-C_6 alkynyl, wherein the substituent on the substituted C_1-C_6 alkyl, substituted C_2-C_6 alkenyl or substituted C_2-C_6 alkynyl is selected from unsubstituted or substituted aryl, heterocyclic, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $R^{10}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NR^{10}$-, $(R^{10})_2N$-C(O)-, CN, $(R^{10})_2N$-C(NR^{10})-, $R^{10}C(O)$-, $R^{10}OC(O)$-, -$N(R^{10})_2$, and $R^{11}OC(O)$-NR^{10}-,

or two R^{1a}s on the same carbon atom may be combined to form -$(CH_2)_t$-;

R^{1b} and R^{1c} are independently selected from:

a) hydrogen,

b) aryl, heterocycle, C_3-C_{10} cycloalkyl, $(R^{10})_2N$-C(O)-, $(R^{10})_2N$-C(NR^{10})-, $R^{10}C(O)$- or $R^{10}OC(O)$-, and

c) unsubstituted or substituted C_1-C_6 alkyl, unsubstituted or substituted C_2-C_6 alkenyl or unsubstituted or substituted C_2-C_6 alkynyl, wherein the substituent on the substituted C_1-C_6 alkyl, substituted C_2-C_6 alkenyl or substituted C_2-C_6 alkynyl is selected from unsubstituted or substituted aryl, heterocyclic, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, one or more fluorines, $R^{10}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NR^{10}$-, $(R^{10})_2N$-C(O)-, CN, $(R^{10})_2N$-C(NR^{10})-, $R^{10}C(O)$-, $R^{10}OC(O)$-, -$N(R^{10})_2$, and $R^{11}OC(O)$-NR^{10}-;

R^2 and R^3 are independently selected from H; unsubstituted or substituted C_{1-8} alkyl, unsubstituted or substituted C_{2-8} alkenyl, unsubstituted or substituted C_{2-8} alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle,



wherein the substituted group is substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with:
   a) C_{1-4} alkyl,
   b) $(CH_2)_pOR^6$,
   c) $(CH_2)_pNR^6R^7$,
   d) halogen,
   e) CN,
2) C_{3-6} cycloalkyl,
3) OR^6,
4) SR^4, $S(O)R^4$, SO_2R^4,

5) $-NR^6R^7$,

6)  ,

7)  ,

8)  ,

9)  ,

10)  ,

11) $-SO_2-NR^6R^7$,

12)  ,

13)  ,

14)  ,

15) N_3, or

16) F; or

R^2 and R^3 are attached to the same carbon atom and are combined to form $-(CH_2)_u-$ wherein one of the carbon atoms is optionally replaced by a moiety selected from O, $S(O)_m$, -NC(O)-, and $-N(COR^{10})-$; and

R^4 is selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, heterocycle, aryl, unsubstituted or substituted with:

a) C_{1-4} alkoxy,

b) aryl or heterocycle,

c) halogen,

d) HO,

e)  ,

f) $—SO_2R^{11}$,

g) $N(R^{10})_2$, or

h) one or more fluorines;

R^5, R^6 and R^7 are independently selected from:

1) hydrogen,

2) $R^{10}C(O)-$, or $R^{10}OC(O)-$, and

3) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_{3-6} cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with one or more substituents selected from:

a) $R^{10}O-$,

b) aryl or heterocycle,

c) halogen,

d) $R^{10}C(O)NR^{10}-$,

e)  ,

f) $—SO_2R^{11}$,

g) $N(R^{10})_2$,
h) C_{3-6} cycloalkyl,
i) C_1-C_6 perfluoroalkyl,
j) $(R^{10})_2N$-$C(NR^{10})$-,
k) $R^{10}OC(O)$-,
l) $R^{11}OC(O)NR^{10}$-,
m) CN, and
n) NO_2; or

R^6 and R^7 may be joined in a ring; and independently,

R^5 and R^7 may be joined in a ring;

R^8 is independently selected from:

a) hydrogen,
b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perfluoroalkyl, F, Cl, Br, $R^{12}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NR^{10}$-, $(R^{10})_2NC(O)$-, $R^{10}{}_2N$-$C(NR^{10})$-, CN, NO_2, $R^{10}C(O)$-, $R^{10}OC(O)$-, $-N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$-, and
c) C_1-C_6 alkyl unsubstituted or substituted by unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perfluoroalkyl, F, Cl, Br, $R^{10}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NH$-, $(R^{10})_2NC(O)$-, $R^{10}{}_2N$-$C(NR^{10})$-, CN, $R^{10}C(O)$-, $R^{10}OC(O)$-, $-N(R^{10})_2$, or $R^{10}OC(O)NH$-;

R^9 is independently selected from:

a) hydrogen,
b) C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perfluoroalkyl, F, Cl, Br, $R^{10}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NR^{10}$-, $(R^{10})_2NC(O)$-, $R^{10}{}_2N$-$C(NR^{10})$-, CN, NO_2, $R^{10}C(O)$-, $R^{10}OC(O)$-, $-N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$-, and
c) C_1-C_6 alkyl unsubstituted or substituted by C_1-C_6 perfluoroalkyl,

F, Cl, Br, $R^{10}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NR^{10}$-, $(R^{10})_2NC(O)$-, $R^{10}{}_2N$-$C(NR^{10})$-, CN, $R^{10}C(O)$-, $R^{10}OC(O)$-, $-N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$-;

R^{10} is independently selected from hydrogen, C_1-C_6 alkyl, C_1-C_6 alkyl substituted with one or more fluorines, benzyl, unsubstituted or substituted aryl and unsubstituted or substituted heterocycle;

R^{11} is independently selected from C_1-C_6 alkyl, C_1-C_6 alkyl substituted with one or more fluorines, unsubstituted or substituted aryl and unsubstituted or substituted heterocycle;

R^{12} is independently selected from hydrogen, C_1-C_6 alkyl, C_1-C_6 alkyl substituted with one or more fluorines, unsubstituted or substituted benzyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, and C_1-C_6 alkyl substituted with unsubstituted or substituted aryl or unsubstituted or substituted heterocycle;

G^1, G^2 and G^3 are independently selected from (R^2,R^3) and O;

V is selected from:

a) heterocycle, and

b) aryl;

W is $S(O)_m$, O or CH_2;

X is selected from: a bond, -C(O)-, $-NR^{10}C(O)$-, $-N(R^{10})S(O)_2$- and $S(O)_2$;

Y is selected from a bond, -C(O)-, $-C(O)NR^{10}$-, -C(O)O-, $-(CR^{1c}{}_2)$- and $-S(O)_m$;

Z is selected from unsubstituted or substituted aryl and unsubstituted or substituted heterocycle, wherein the substituted aryl or substituted heterocycle is substituted with one or more of:

1) C_{1-8} alkyl, C_{2-8} alkenyl or C_{2-8} alkynyl, unsubstituted or substituted with:

a) C_{1-4} alkoxy,
b) NR^6R^7,
c) C_{3-6} cycloalkyl,
d) aryl or heterocycle,
e) HO,
f) $-S(O)_mR^4$,
g) $-C(O)NR^6R^7$, or
h) one or more fluorines;

2) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle,
3) halogen,
4) OR^6,
5) NR^6R^7,
6) CN,
7) NO_2,
8) CF_3;
9) $-S(O)_mR^4$,
10) $-OS(O)_2R^4$,
11) $-C(O)NR^6R^7$,
12) $-C(O)OR^6$, or
13) C_3-C_6 cycloalkyl;

m is independently 0, 1 or 2;
p is independently 0, 1, 2, 3 or 4;
q is 1 or 2;
r is 0 to 5;
s is 1 or 2;
t is 2, 3, 4, 5 or 6; and
u is 2, 3, 4 or 5;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to Claim 1 of the formula B:



B

wherein:

R^{1a} is independently selected from:

a) hydrogen,

b) $R^{10}O$-, -$N(R^{10})_2$, $R^{10}C(O)NR^{10}$-, $R^{11}OC(O)O$- or $R^{11}OC(O)NR^{10}$-, and

c) C_1-C_6 alkyl, unsubstituted or substituted by $R^{10}O$-, -$N(R^{10})_2$, $R^{10}C(O)NR^{10}$-, $R^{11}OC(O)O$-, $R^{11}OC(O)NR^{10}$- or $R^{11}S(O)_m$-;

R^{1b} and R^{1c} are independently selected from:

a) hydrogen, and

b) unsubstituted or substituted C_1-C_6 alkyl, wherein the substituent on the substituted C_1-C_6 alkyl is selected from one or more fluorines, $R^{10}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NR^{10}$-, $R^{10}OC(O)O$- and $R^{11}OC(O)$-NR^{10}-;

R^3 is selected from H and CH_3;

R^2 is selected from H;



and C_{1-5} alkyl, unbranched or branched, unsubstituted or substituted with one or more of:

1) aryl,
2) heterocycle,
3) OR^6,
4) SR^4, SO_2R^4, or
5) 

and any two of R^2 and R^3 are optionally attached to the same carbon atom;

R^4 is selected from:

C_{1-4} alkyl and C_{3-6} cycloalkyl, unsubstituted or substituted with:

a) C_{1-4} alkoxy,
b) one or more fluorines, or
c) aryl or heterocycle;

R^6 and R^7 are independently selected from H; C_{1-6} alkyl, C_{3-6} cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with one or two:

a) C_{1-4} alkoxy,
b) aryl or heterocycle,
c) halogen,
d) HO,
e) 
f) $—SO_2R^{11}$,
g) $N(R^{10})_2$, or
h) C_{3-6} cycloalkyl;

R^8 is independently selected from:

a) hydrogen,

b) unsubstituted or substituted aryl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perfluoroalkyl, F, Cl, $R^{12}O$-, $R^{10}C(O)NR^{10}$-, CN, NO_2, $(R^{10})_2N$-$C(NR^{10})$-, $R^{10}C(O)$-, -$N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$-, and

c) C_1-C_6 alkyl substituted by: unsubstituted or substituted aryl, C_1-C_6 perfluoroalkyl, $R^{10}O$-, $R^{10}C(O)NR^{10}$-, $(R^{10})_2N$-$C(NR^{10})$-, $R^{10}C(O)$-, -$N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$-;

R^{10} is independently selected from hydrogen, C_1-C_6 alkyl, C_1-C_6 alkyl substituted with one or more fluorines, benzyl and unsubstituted or substituted aryl;

R^{11} is independently selected from C_1-C_6 alkyl, C_1-C_6 alkyl substituted with one or more fluorines, and unsubstituted or substituted aryl;

R^{12} is independently selected from hydrogen, C_1-C_6 alkyl, unsubstituted or substituted benzyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, and C_1-C_6 alkyl substituted with one or more fluorines, unsubstituted or substituted aryl or unsubstituted or substituted heterocycle;

G^1 and G^2 are independently selected from (R^2,R^3) and O;

V is selected from:

a) heterocycle selected from pyridinyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl and isoquinolinyl, and

b) aryl;

W is S or CH_2;

X is selected from a bond, -C(O)- or -$S(O)_m$;

Y is selected from a bond, -C(O)-, -$C(O)NR^{10}$-, -C(O)O-, -$(CR^{1c}{}_2)$- and -$S(O)_m$;

Z is selected from unsubstituted or substituted aryl or unsubstituted or substituted heterocycle, wherein the substituted aryl or substituted heterocycle is independently substituted with one or two of:

1) C_{1-8} alkyl, C_{2-8} alkenyl or C_{2-8} alkynyl, unsubstituted or substituted with:
   a) C_{1-4} alkoxy,
   b) NR^6R^7,
   c) C_{3-6} cycloalkyl,
   d) aryl or heterocycle,
   e) HO,
   f) $-S(O)_mR^4$,
   g) $-C(O)NR^6R^7$, or
   h) one or more fluorines;
2) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle,
3) halogen,
4) OR^6,
5) NR^6R^7,
6) CN,
7) NO_2,
8) CF_3,
9) $-S(O)_mR^4$,
10) $-OS(O)_2R^4$,
11) $-C(O)NR^6R^7$,
12) $-C(O)OR^6$, or
13) C_3-C_6 cycloalkyl;

m is 0, 1 or 2;
n is 0, 1 or 2;
p is 0, 1, 2, 3 or 4;
q is 1 or 2; and
r is 0 to 5;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound according to Claim 2 of the formula C:



C

wherein:

R^{1a} is independently selected from:

a) hydrogen,

b) $R^{10}O$-, -$N(R^{10})_2$, $R^{10}C(O)NR^{10}$-, $R^{11}OC(O)O$- or $R^{11}OC(O)NR^{10}$-, and

c) C_1-C_6 alkyl, unsubstituted or substituted by $R^{10}O$-, -$N(R^{10})_2$, $R^{10}C(O)NR^{10}$-, $R^{11}OC(O)O$-, $R^{11}OC(O)NR^{10}$- or $R^{11}S(O)_m$-;

R^{1b} is selected from:

a) hydrogen, and

b) unsubstituted or substituted C_1-C_6 alkyl, wherein the substituent on the substituted C_1-C_6 alkyl is selected from one or more fluorines, $R^{10}O$-, $R^{11}S(O)_m$-, $R^{10}C(O)NR^{10}$-, $R^{10}OC(O)O$- and $R^{11}OC(O)$-NR^{10}-;

R^3 is selected from H and CH_3;

R^2 is selected from H;



and C_{1-5} alkyl, unbranched or branched, unsubstituted or substituted with one or more of:

1) aryl,
2) heterocycle,
3) OR^6,
4) SR^4, SO_2R^4, or
5) 

and any two of R^2 and R^3 are optionally attached to the same carbon atom;

R^4 is selected from:

C_{1-4} alkyl and C_{3-6} cycloalkyl, unsubstituted or substituted with:

a) C_{1-4} alkoxy,
b) one or more fluorines, or
c) aryl or heterocycle;

R^6 and R^7 are independently selected from H; C_{1-6} alkyl, C_{3-6} cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with one or two:

a) C_{1-4} alkoxy,
b) aryl or heterocycle,
c) halogen,
d) HO,
e) 
f) $—SO_2R^{11}$,
g) $N(R^{10})_2$, or
h) C_{3-6} cycloalkyl;

R^8 is independently selected from:

a) hydrogen,

b) unsubstituted or substituted aryl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perfluoroalkyl, F, Cl, $R^{12}O$-, $R^{10}C(O)NR^{10}$-, CN, NO_2, $(R^{10})_2N$-$C(NR^{10})$-, $R^{10}C(O)$-, -$N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$-, and

c) C_1-C_6 alkyl substituted by: unsubstituted or substituted aryl, C_1-C_6 perfluoroalkyl, $R^{10}O$-, $R^{10}C(O)NR^{10}$-, $(R^{10})_2N$-$C(NR^{10})$-, $R^{10}C(O)$-, -$N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$-;

R^{10} is independently selected from hydrogen, C_1-C_6 alkyl, C_1-C_6 alkyl substituted with one or more fluorines, benzyl and unsubstituted or substituted aryl;

R^{11} is independently selected from C_1-C_6 alkyl, C_1-C_6 alkyl substituted with one or more fluorines and unsubstituted or substituted aryl;

R^{12} is independently selected from hydrogen, C_1-C_6 alkyl, unsubstituted or substituted benzyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, and C_1-C_6 alkyl substituted with one or more fluorines, unsubstituted or substituted aryl or unsubstituted or substituted heterocycle;

G^1 is selected from (R^2,R^3) and O;

W is S or CH_2;

X is selected from a bond, -C(O)- or -$S(O)_m$;

Y is selected from a bond, -C(O)-, -$C(O)NR^{10}$-, -C(O)O-, or -$S(O)_m$;

Z is selected from unsubstituted or substituted aryl or unsubstituted or substituted heterocycle, wherein the substituted aryl or substituted heterocycle is independently substituted with one or two of:

1) C_{1-8} alkyl, C_{2-8} alkenyl or C_{2-8} alkynyl, unsubstituted or substituted with:
   a) C_{1-4} alkoxy,
   b) NR^6R^7,
   c) C_{3-6} cycloalkyl,
   d) aryl or heterocycle,
   e) HO,
   f) $-S(O)_mR^4$,
   g) $-C(O)NR^6R^7$, or
   h) one or more fluorines;
2) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle,
3) halogen,
4) OR^6,
5) NR^6R^7,
6) CN,
7) NO_2,
8) CF_3,
9) $-S(O)_mR^4$,
10) $-OS(O)_2R^4$,
11) $-C(O)NR^6R^7$,
12) $-C(O)OR^6$, or
13) C_3-C_6 cycloalkyl;

m is 0, 1 or 2;
n is 0, 1 or 2;
p is 0, 1, 2, 3 or 4;
q is 1 or 2; and
r is 0 to 5;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. A compound which is selected from:

(3*R*) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole

(3*S*) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole

5-[1-[4-(3-chlorophenyl)-3-oxo-piperazin-1-ylmethyl]-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole

5-{1-[4-(3-Chlorophenyl)-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole

(3*R*) 5-{1-[(2*S*) 2-butyl -4-(3-methoxyphenyl)-5-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole

(3*S*) 5-{1-[(2*S*) 2-butyl-4-(3-methoxyphenyl)-5-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole

(3*R*) 3-(4-Cyanophenyl)-5-{1-[(2*S*) 4-(3-methoxyphenyl)-5-oxo-2-(2-thienylmethyl)-1-piperazinyl]-methanoyl}-2,3-dihydro-imidazo[2,1-b]thiazole

(3*S*) 3-(4-Cyanophenyl)-5-{1-[(2*S*) 4-(3-methoxyphenyl)-5-oxo-2-(2-thienylmethyl)-1-piperazinyl]-methanoyl}-2,3-dihydro-imidazo[2,1-b]thiazole

(1*R*,*S*) (3*R*) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-1-oxo-2,3-dihydro-imidazo[2,1-b]thiazole

(1*R*,*S*) (3*S*) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-1-oxo-2,3-dihydro-imidazo[2,1-b]thiazole

(3*R*) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-1,1-dioxo-2,3-dihydro-imidazo[2,1-b]thiazole

(3*S*) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-1,1-dioxo-2,3-dihydro-imidazo[2,1-b]thiazole

3-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methyl}-5-(4-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine

(5*R*) 3-{1-[4-(3-chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-5-(4-cyanophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole

(5*S*) 3-{1-[4-(3-chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-5-(4-cyanophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole

5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-3-methyl-2,3-dihydroimidazo[2,1-b]thiazole

5-{1-[4-(2-Bromo-5-(allyloxy)benzyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole

3-{1-[4-(2-chloro-5-hydroxybenzyl)-3-oxo-piperazin-1-yl]-methanoyl}-5-(4-cyano-3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. A compound according to Claim 4 which is selected from:

(3*R*) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole



(3*S*) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole



(5*R*) 3-{1-[4-(3-chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-5-(4-cyanophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole



(5*S*) 3-{1-[4-(3-chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-5-(4-cyanophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole



or a pharmaceutically acceptable salt or stereoisomer thereof.

6. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

7. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 3.

8. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 4.

9. A method for inhibiting prenyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 6.

10. A method for inhibiting prenyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 7.

11. A method for inhibiting prenyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 8.

12. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 6.

13. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 7.

14. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 8.

15. A method for treating neurofibromin benign proliferative disorder which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 6.

16. A method for treating blindness related to retinal vascularization which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 6.

17. A method for treating infections from hepatitis delta and related viruses which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 6.

18. A method for preventing restenosis which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 6.

19. A method for treating polycystic kidney disease which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 6.

20. A method of conferring radiation sensitivity on a tumor cell using a therapeutically effective amount of a composition of Claim 6 in combination with radiation therapy.

21. A method of using a therapeutically effective amount of a composition of Claim 6 in combination with an antineoplastic to treat cancer.

22. A method according to Claim 21 wherein the antineoplastic is paclitaxel.

23. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

24. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.